Goodwin

Recognised for its transactional strength, Goodwin is well-placed to advise companies and investors in life sciences and healthcare on financings, investments, M&A and joint ventures. The ‘seamless’ team is jointly led by David Mardle, who advises emerging companies on corporate and capital markets transactions; Graham Defries, who focuses on funding and collaboration transactions for biotech and pharma companies and investors; Sophie McGrath, experienced in a range of corporate matters at all stages of development; and ’highly attentive’ Arvin Abraham, who specialises in PE, VC and strategic investments in medtech, medical devices, digital health and healthcare services. Maria Dragun, promoted to partner in October 2024, is noted for her attention to detail in cross-border transactions. Anna Humphrey joined from Orrick in January 2025, strengthening the team’s employee incentives sector expertise. Hayley Davis is no longer at the firm.